Used in the treatment of autoimmune and inflammatory diseases by targeting the OX40L pathway, this antibody (amlitelimab) helps modulate T-cell activation. It is being investigated for conditions such as atopic dermatitis, psoriasis, and other immune-mediated disorders like rheumatoid arthritis and interstitial lung disease.

By blocking the interaction between OX40 and OX40L on T cells, it reduces abnormal immune activation and inflammatory responses, offering potential for improved disease control with fewer side effects compared to broad immunosuppressants.

Clinical studies have shown that amlitelimab significantly reduces symptoms such as itching, redness, and skin thickening in patients with atopic dermatitis, with good long-term safety. It has potential as a new treatment option for patients who do not respond to conventional therapies.